BACKGROUND:Acamprosate is a newly registered drug that appears to reduce alcohol-drinking in both animal models and clinical conditions. METHOD: In order to assess the efficacy and safety of the drug in the treatment of detoxified alcoholics, we performed a 90-day double-blind trial comparing two dosages of acamprosate (1332 mg/day and 1998 mg/day). RESULTS: For all efficacy parameters, acamprosate appeared to be significantly superior to placebo, with a trend towards a better effect at the higher dosage. Furthermore, acamprosate appeared to be extremely safe. CONCLUSION: This study confirms that acamprosate could be an interesting adjuvant for maintaining abstinence in detoxified alcoholics.
RCT Entities:
BACKGROUND:Acamprosate is a newly registered drug that appears to reduce alcohol-drinking in both animal models and clinical conditions. METHOD: In order to assess the efficacy and safety of the drug in the treatment of detoxified alcoholics, we performed a 90-day double-blind trial comparing two dosages of acamprosate (1332 mg/day and 1998 mg/day). RESULTS: For all efficacy parameters, acamprosate appeared to be significantly superior to placebo, with a trend towards a better effect at the higher dosage. Furthermore, acamprosate appeared to be extremely safe. CONCLUSION: This study confirms that acamprosate could be an interesting adjuvant for maintaining abstinence in detoxified alcoholics.
Authors: John C Umhau; Melanie L Schwandt; Julie Usala; Christopher Geyer; Erick Singley; David T George; Markus Heilig Journal: Neuropsychopharmacology Date: 2011-02-02 Impact factor: 7.853
Authors: Helen M Pettinati; Kyle M Kampman; Kevin G Lynch; Hu Xie; Charles Dackis; Amanda R Rabinowitz; Charles P O'Brien Journal: Addict Behav Date: 2007-11-17 Impact factor: 3.913
Authors: Raye Z Litten; I-Jen P Castle; Daniel Falk; Megan Ryan; Joanne Fertig; Chiung M Chen; Hsiao-ye Yi Journal: Alcohol Clin Exp Res Date: 2013-07-24 Impact factor: 3.455
Authors: Roel Verheul; Philippe Lehert; Peter J Geerlings; Maarten W J Koeter; Wim van den Brink Journal: Psychopharmacology (Berl) Date: 2004-08-19 Impact factor: 4.530